Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Invitris is a 2022-founded biotech startup building Phactory, a cell-free protein synthesis platform for rapid design and scalable production of synthetic proteins and bacteriophages for antimicrobial resistance and broader protein therapeutics.
Primary product
Phactory cell-free protein synthesis platform
Founded
2022
Headquarters
Am Klopferspitz 19, 82152 Planegg-Martinsried, Germany
Team size
20-30
Industry
Biotechnology
Sub-industry
Cell-free protein synthesis and phage therapeutics
Offices
0 jobs at Invitris
Check back later for new openings
Business model
Stage
early-stage grant- and seed-backed
Latest round
EIC Accelerator grant and equity · Mar 2025
Latest amount
$12.5M
EIC Accelerator grant and equity
Mar 2025 · EIC Accelerator
Oct 2024
Jan 2024 · Vehiculum Capital
Sep 2023 · Mergus Ventures
May 2023 · INCATE
Apr 2023 · Y Combinator
Jan 2022 · INCATE
Leadership
CEO & Co-Founder
Co-Founder & Scientific Lead
Head of Translational Partnerships
VP Platform Automation
Investors
Research-driven biotech startup with a young, collaborative team; public hiring posts emphasize hands-on lab work at IZB Martinsried and student/intern pathways.
Compensation
No public salary bands or compensation policy found in the reviewed sources.
Pricing
Custom B2B co-development, licensing, and services; no public price list.
Differentiators
Technology
Customers
Competitors
Estimated revenue
≈$4M estimated annual revenue (2024)
Estimated monthly visits
772
Traffic estimate as of Jul 2026
LinkedIn · Jul 2026
Invitris recapped VoM 2026 in Prague and said its CEO Patrick Grossmann, co-founder Kilian Vogele, and Head of Translational Partnerships Matthias Steiger spent the week meeting phage researchers and presenting the AI-to-Cell-Free Challenge.
LinkedIn · Jul 2026
The company launched its AI-to-Phage Challenge at Viruses of Microbes 2026 in Prague, positioning the initiative around antimicrobial resistance and AI-driven phage discovery.
LinkedIn · Jul 2026
Invitris announced its attendance at VoM 2026 and invited collaborators to meet the team and learn about the upcoming AI-to-Cell-Free Phage Challenge.
Phage Directory / YouTube · Jun 2026
Podovirus podcast episode featuring co-founder Kilian Vogele discussing cell-free phage synthesis, manufacturing challenges, and the company's long-term vision for decentralized phage production.
IZB · Mar 2025
IZB reported that Invitris was selected for the EIC Accelerator, describing it as multi-million-euro non-dilutive funding plus equity to scale the Phactory platform and accelerate personalized protein-based therapies.